Pharma Focus Asia

The University of Texas MD Anderson Cancer Centre Develops Breakthrough PRAME-targeted TCR NK Cell Therapy

The University of Texas MD Anderson Cancer Centre has developed PRAME TCR/IL-15 NK (SY-307), a revolutionary therapy using engineered T cell receptor natural killer (TCR NK) cells to target relapsed/refractory myeloid malignancies.

These engineered cells are derived from cord blood and are equipped with a high-affinity TCR specifically designed to target the PRAME tumour-associated neoantigen. 

PRAME is notable for its widespread presence across various cancer types, including acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), as well as melanoma, sarcoma, and several solid tumours like ovarian, endometrial, lung, and breast cancer.

The distinct immunogenicity of PRAME, combined with its selective expression in cancerous tissues, positions it as an ideal target for cell therapy-based cancer immunotherapy. 

Being a well-known cancer-testis antigen, PRAME is characterised by its re-expression in cancer cells while maintaining minimal expression in normal tissues, making it a promising avenue for immunotherapy.

Research on PRAME, initially focusing on haematological malignancies and later extending to solid tumours, promises to deepen understanding of the potential benefits of engineered TCR-modified NK cells for patients dealing with relapsed/refractory myeloid malignancies. 

This development marks a significant step forward in the creation of readily available engineered TCR NK cell therapies to tackle pressing medical needs.

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference